Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

Zoetis is the undisputed leader in the global animal health industry, and we believe it possesses the widest moat of all the competitors. Zoetis has set itself apart based on its impressive innovation ...

Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...

Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

President Donald Trump has rolled out his plans to increase U.S. tariffs to match the tax rates that other countries charge ...

COEP Venture Group aims to identify, invest in, and support high-potential startups shaping the future of automation, intelligent systems, and AI-driven enterprise solutions. By providing capital, ...

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs ...